Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q2 2026 · 10-Q
Revenue—
Net Income-$26.79M-$26.79MN/M vs Q2 2025 EPS Diluted-$0.22-$0.22N/M vs Q2 2025 Operating Income-$29,258,000N/M Operating Cash Flowderived-$20,650,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Free Cash Flowderived-$34,845,000N/M ended Jun 30, 2026 · filed Aug 10, 2026 · 41 d after period end